

Reference number(s)

5076-A

Supplemental Specialty Prior Authorization Livtencity

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Livtencity	maribavir

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹

Livtencity is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Treatment of Post-Transplant Cytomegalovirus Infection^{1,2}

Livtencity Supplemental Specialty PA 5076-A P2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s) 5076-A

Authorization of 3 months may be granted for treatment of cytomegalovirus when all of the following criteria are met:

- The patient is a recipient of a hematopoietic stem cell transplant (HSCT) or a solid organ transplant.
- The patient is 12 years of age or older and weighs at least 35 kilograms.
- Disease is refractory to at least one antiviral treatment for cytomegalovirus (e.g., ganciclovir, valganciclovir, cidofovir, or foscarnet).

Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria section.

References

- 1. Livtencity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; March 2024.
- 2. Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900-931.